Use of Bone Scintigraphy, CT and MRI in Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by University of Aarhus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00682253
First received: May 20, 2008
Last updated: September 8, 2009
Last verified: September 2009

May 20, 2008
September 8, 2009
May 2008
March 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00682253 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Use of Bone Scintigraphy, CT and MRI in Breast Cancer
Use og Bone Scintigraphy, CT and MRI for Detection of Metastases in Patients With Breast Cancer

A new imaging modality combining CT and tomographic bone scintigraphy (SPECT/CT) has enabled the combination of functional and anatomical imaging. Its use in cancer patients has not yet been evaluated or validated against a relative gold stand or clinical follow up. The purposes of this study are: 1: to validate the use of conventional planar bone scintigraphy and SPECT combined with low-dose or diagnostic CT and compare this to 3 Tesla MRI and clinical follow up. 2: to compare the specificity of low-dose and diagnostic CT, respectively, combined with bone SPECT. 3: to construct an algorithm for optimal evaluation of disease dissemination in breast cancer patients

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

women aged 18-80 years with suspicision of disseminated breast cancer seen at Dept. of Oncology, Aarhus University Hospital

Breast Neoplasms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
180
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological verified breast cancer
  • Age 18-80 years
  • Investigation for metastases using imaging modality/modalities planned
  • Written consent to participate in trial

Exclusion Criteria:

  • Overweight limiting the use of MRI
  • Metal parts in body
  • Claustrophobia
  • Allergy to contrast agents used in trial
  • Pregnancy
Female
18 Years to 80 Years
No
Contact: Anni Eskild-Jensen, MD, PhD, DMSci +45 8949 2251 aej@ki.au.dk
Denmark
 
NCT00682253
SKF-0805
Not Provided
Anni Eskild-Jensen, Aarhus University Hospital
University of Aarhus
Not Provided
Not Provided
University of Aarhus
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP